FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
06/06/2025
Back to search
Official data from USPTO
INOVIQ
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
INOVIQ
ST13
US500000079349962Class
5, 10, 42
Filing
79349962
Registration
7601786
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
04/03/2026
Trademark type
Word
Nice classes
5, 10, 42
Filing date
05/20/2022
Registration date
12/17/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/17/2024
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
AU
Examiner
BRUNDAGE, DAVID WILLIAM
Law office
M30
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
INOVIQ Limited
Representatives
Charles G. Zug Nelson Mullins Riley & Scarborough LLP
Technical classification
Nice Classes
Class 5Class 10Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticalbiotechnology and medical preparations and substances for the preventiondiagnosis or treatment of cancerneurodegenerativecardiovascularinflammatorymetabolic diseases; pharmaceuticalbiotechnology and medical preparations and substances for the treatmentreconstruction and repair of cancerneurodegenerativecardiovascularinflammatorymetabolic diseases using antibodies or exosomes; diagnostic preparations and reagents for medical purposes; diagnostic preparations for medical laboratory use and reagents for medical diagnostic useextracellular vesiclesRNAprotein arrays or monoclonal antibodies; monoclonal antibodies for medical purposes; monoclonal antibody fragments for medical purposes; monoclonal antibody conjugates for medical purposes; preparations for the treatmentreconstruction and repair of cancerneurodegenerativecardiovascularinflammatorymetabolic diseases using antibodies; immunological antibodies for medical use; monoclonal antibodies for diagnostic medical use; monoclonal antibodies for medical use; monoclonal antibodies for therapeutic purposes; products containing antibodies for use in medicineextracellular vesiclesRNAprotein arrays or monoclonal antibodies; proteins for medical use in binding antibodies; proteins for medical use in detecting antibodies; reagents for use in the development of monoclonal antibodies for medical purposes; tagged antibodies for medical use; vaccines; vaccines against cancer viral or bacterial infection; vaccines for human use; vaccine adjuvants; diagnostic preparationsreagentspharmaceutical and biochemical anti-cancer substancesproducts for the preventiondiagnosis or treatment of cancerneurodegenerativeinflammatorymetabolic diseasestesting materialsdiagnostic test stripsimmunoassaysPCR or genetic tests for in-vitro diagnostic use for medical purposes; diagnostic preparations and reagents for medical purposesdiagnostic biomarker reagents; reagents for use in diagnostic tests for medical purposes; reagents for medical diagnosis; proteins for use in recombinant DNA technology for medical diagnosis purposes; proteinsnamely protein arrays for use in recombinant DNA technology for medical diagnosis purposes; biological reagents for use in molecular biology for medical purposes
Class 10
Biotechnology medical apparatus for the preventiondiagnosis or treatment of cancerneurodegenerativeinflammatorymetabolic diseases; biotechnology medical apparatusmedical apparatus for the capture of extracellular vesicles; medical diagnostic apparatus and instruments for testing biofluidsplasmaserumsalivaurine and cell cultures for sale in kit form
Class 42
Scientific researchclinical researchdevelopmentadvisory and consultancy services in relation to antibody production; vaccine screeningin the nature of research and development of vaccines; advisory services relating to diagnostic products for scientific research; advisory services relating to diagnostic products for scientific researchnamely development of diagnostic products for scientific researchextracellular vesical (EV) isolationscreating custom NET buildsdeveloping diagnostic assays; computer-aided diagnostic testing services for others for scientific research purposes; scientific research for medical purposes; scientific research for medical purposesresearch services relating to diagnostic products for scientific researchextracellular vesical (EV) isolationscreating custom NET buildsdeveloping diagnostic assays; research services in the field of diagnostic preparations; preparation of reports relating to medicalscientific and technical research; provision of information relating to medicalscientific and technical research; research and development of products; research and development of products in the field of antibody generation; research and development of productsnew therapeutic products in the field of gene therapeutics and cell therapeutics; research and development of productsextracellular vesicle-based diagnostic productsextracellular vesicle-based therapeutic products; laboratory research in the fields of analytical chemistrybiochemistrymedicinal chemistrydrug developmentbiotechnologymicrobiology and molecular biology; laboratory research services relating to research in the field of extracellular vesicle-based diagnostics and extracellular vesicle-based therapeutics; scientific laboratory research and analysis services; scientific laboratory research and analysis services for research and analysis of new products in the field of cell therapeutics; scientific laboratory research and analysis services for research and analysis of new productsextracellular vesicle-based diagnostic productsextracellular vesicle-based therapeutic products; analysis of tissues for medical research; research and development services in the field of antibody generation; molecular target discovery and development services; recombinant human protein production cell lineculturing of cells for others for scientific research purposes
Publications
History of USPTO decisions and trademark events.
29 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/19/2025
FIMP
FINAL DISPOSITION PROCESSED
05/19/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/17/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/17/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
12/17/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/15/2024
PUBO
PUBLISHED FOR OPPOSITION
10/15/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/25/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/11/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
09/11/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/11/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
09/11/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/11/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/07/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/07/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/07/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
03/11/2024
RFNT
REFUSAL PROCESSED BY IB
02/26/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/21/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
02/21/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/07/2024
RFRR
REFUSAL PROCESSED BY MPU
02/07/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/22/2023
CNRT
NON-FINAL ACTION WRITTEN
03/21/2023
DOCK
ASSIGNED TO EXAMINER
03/10/2023
MAFR
APPLICATION FILING RECEIPT MAILED
09/24/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/20/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/16/2022
Continuous trademark protection
Get notified about every new filing that threatens INOVIQ or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.